Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | ACACA | Q13085 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
| ▸ | GGT1 | P19440 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL364285 | 0.79 | — | — | |
| SCHEMBL13865671 | 0.77 | CYP4F2 (0.33) | CYP4F2CYP4A11 | |
| Ammonia Solution, Strong SCHEMBL27774285 | 0.77 | ACLY (0.46) | TSHRACLYALDH1A1ACACBACACA | |
| SCHEMBL9837458 | 0.77 | ACLY (0.46) | TSHRACLYALDH1A1ACACBACACA | |
| SCHEMBL2151949 | 0.77 | ACLY (0.46) | TSHRACLYALDH1A1ACACBACACA | |
| Carbonotrithioic Acid SCHEMBL28987370 | 0.70 | ACLY (0.41) | TSHRACLYALDH1A1ACACBACACA | |
| SCHEMBL1515614 | 0.69 | — | — | |
| SCHEMBL13373881 | 0.69 | — | — | |
| SCHEMBL13504538 | 0.69 | — | — | |
| SCHEMBL2911089 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809446-B2 | Substituted 3-oxopentanoates and their uses in coating compositions | EASTMAN CHEMICAL COMPANY (US) | 2014-08-19 | — | — | US | disclosed |
| EP-2651873-A1 | SUBSTITUTED 3-OXOPENTANOATES AND THEIR USES IN COATING COMPOSITIONS | Eastman Chemical Company (US) | 2013-10-23 | — | — | EP | disclosed |
| US-20120157609-A1 | SUBSTITUTED 3-OXOPENTANOATES AND THEIR USES IN COATING COMPOSITIONS | EASTMAN CHEMICAL COMPANY (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2012082340-A1 | SUBSTITUTED 3-OXOPENTANOATES AND THEIR USES IN COATING COMPOSITIONS | EASTMAN CHEMICAL COMPANY (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157609-A1 | SUBSTITUTED 3-OXOPENTANOATES AND THEIR USES IN COATING COMPOSITIONS | OXER1, C9, OXGR1 | TSHR 4200/4885ACLY 3179/4885ALDH1A1 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.